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Abstract 
Background: Left ventricular pump function requires a complex interplay 
involving myocardial fibers orientated in the longitudinal, oblique and 
circumferential directions. Long axis dysfunction is an early marker for several 
pathological states. In fact, assessment of long axis function can provide 
independent prognostic information in patients with left ventricular dysfunction. 
Currently, longitudinal systolic function can be evaluated either by cardiac 
magnetic resonance or echocardiography, using two main techniques: mitral 
annular plane systolic excursion (MAPSE) and global longitudinal strain (GLS). 
The aims of these Cardiac Magnetic Resonance (CMR) studies were therefore:  
1. To assess whether lateral MAPSE, as a surrogate for long axis function, is a 
predictor of major adverse cardiovascular events (MACE).  
2. To evaluate the prognostic value of lateral MAPSE in a large multicenter sample 
of patients with reduced ejection fraction (EF).  
3. To evaluate if lateral MAPSE may provide incremental prognostic information 
in patients with hypertension. 
4. To assess whether CMR feature-tracking derived GLS may provide independent 
prognostic information in patients with cardiomyopathy in a single center and then 
in a multicenter study.  
Methods: Study 1. Patients referred at the Illinois University of Chicago for clinical 
CMR with both cine and late gate enhancement (LGE) imaging were prospectively 
enrolled. Patients were followed for the combined primary outcome of MACE: 
death, non-fatal myocardial infarction, hospitalization for heart failure or unstable 
angina, and late revascularization (>90 days after CMR). 
Study 2, 3, 4. Four geographically diverse universities in the United States 
participated in these observational, multicenter studies. We enrolled patients that 
had undergone clinical CMR at the involved Universities with both cine and late 
gate enhancement (LGE) imaging. Patients were followed for the primary outcome 
of all-cause mortality using the Social Security Death Index. 
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Lateral MAPSE was measured in 4 chamber view as the simple linear displacement 
between end-diastole and end-systole. 
Endocardial left ventricular contours were manually traced in all 3 long-axis cine 
views to derive GLS using the Qstrain feature tracking package. 
Results: Study 1. Patients with reduced lateral MAPSE experienced significantly 
higher incidence of MACE. After adjustment for established clinical risk factors 
which were univariate predictors, lateral MAPSE remained a significant 
independent predictor of MACE. Incorporation of lateral MAPSE into this risk 
model resulted in a net reclassification improvement (NRI). 
Study 2. In patients with lower tertiles of lateral MAPSE the risk of death increased 
significantly. After adjustment for risk factors which were univariate predictors, 
lateral MAPSE remained a significant independent predictor of death. Addition of 
lateral MAPSE to this model resulted in significant improvement in model 
discrimination.  
Study 3. In patients with hypertension lateral MAPSE is a significant independent 
predictor of mortality. By Kaplan-Meier-analysis, the risk-of-death was 
significantly higher in patients with lateral MAPSE<median (10mm). Lateral 
MAPSE was associated with an increased risk-of-death after adjustment for clinical 
and imaging risk factors. Addition of lateral MAPSE in this model resulted in 
significant-improvement in the C-statistic. Moreover, lateral MAPSE remained 
independently associated with death amongst the subgroup of patients with 
preserved EF as well as in those without a history of myocardial infarction. 
Study 4. The risk of death increased significantly with decreasing tertiles of GLS. 
After adjustment for risk factors, which were univariate predictors, GLS remained 
a significant independent predictor of death. Addition of GLS to this model resulted 
in significant improvement in the global chi-square and C statistic. 
 
Conclusions: Reduced long axis function assessed either with lateral MAPSE or 
GLS during routine cine-CMR is an independent predictor of MACE and all-cause 
mortality in patients with left ventricle (LV) disfunction and in hypertensives 
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patients incremental to common clinical and imaging risk factors including EF and 
LGE. Future studies are needed to explore the role of CMR derived lateral MAPSE 
and GLS in clinical decision making for these patients. 
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Background 
 
Longitudinal function of heart 
Cardiac pumping is the result of the contraction of myocardial fibers organized in 
different orientations and different layers1 2 (figure 1), resulting in longitudinal and 
circumferential shortening and radial thickening of the ventricles3 (figure 2). Most 
of left ventricular fibres are arranged circumferentially, particularly in the mid-wall 
and the base of the ventricle, however longitudinal fibres are found in the 
subendocardial and subepicardial free wall as well as in the papillary muscles. 
Longitudinal shortening can be observed as the movement of the base of the 
ventricles toward the apex in systole4 5. Longitudinal function plays a fundamental 
role in cardiac movement, contributing to ventricular ejection by reducing 
longitudinal left ventricle cavity size as the mitral annulus is pulled toward the apex, 
and has been shown to be an important contributor to left ventricular ejection6.  
During early diastole, the potential energy stored during systole creates ventricular 
suction, critical in facilitating rapid ventricular filling at low pressures in the normal 
heart7. As the mitral annulus springs back to its equilibrium position, it moves 
around the column of blood passing through the mitral valve, thus aiding ventricular 
filling. Through this simple mechanism, blood that was in the left atrium finds itself 
in the ventricle despite remaining stationary with respect to the apex and chest wall. 
The motion of the annulus towards the apex during ventricular systole has the effect 
of correspondingly increasing the capacity of the atrium as its floor moves 
downwards - thus drawing blood into the atrium from the pulmonary veins6 8. 
During atrial systole, atrial emptying and ventricular filling are further facilitated 
as the mitral annulus is pulled away from the apex by contraction of atrial 
myocardium, which is inserted into it9.  
Thus, longitudinal movement of the mitral annulus is a major component of normal 
heart function. Longitudinal annular movement therefore appears to be a dominant 
contributor to left ventricular pump function in adults. CMR has been used to 
measure the contribution of long axis function to overall stroke volume in normal 
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subjects, elite athletes and patients with dilated cardiomyopathy 6. Several studies 
have demonstrated that as much as 60% of stroke volume is explained by 
longitudinal function10.  
Possibly because of their subendocardial location, most of longitudinal myocardial 
fibers seem to be exquisitely sensitive to disturbance by various pathologies11. 
Mitral annular motion is rapidly affected by ischemia and there is a very close 
interaction between long axis function and coronary artery disease12 
 
 
Figure 1. Myocardial fibers of heart. Longitudinal fibers are superficial, circumferential are 
located in the middle myocardium, oblique fibers are in the deep myocardium 
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Figure 2. Radial thickening, longitudinal and circumferential shortening of the left ventricle 
 
 
 
Assessment of left ventricle longitudinal systolic function 
Assessment of longitudinal systolic function may overcome most limitations of 
standard systolic indices and offer detailed additional information, therefore 
providing a valid integration to classic measures of global and circumferential 
systolic performance. Currently, longitudinal systolic performance can be evaluated 
either by cardiac magnetic resonance or by echocardiography, using two main 
techniques: MAPSE and GLS. 
 
MAPSE 
Since the cardiac apex is fixed with respect to the chest wall, changes in long axis 
function can be assessed by measuring changes in the position of the 
atrioventricular annulus11. Indeed, early studies used M-mode echocardiography to 
directly follow the position of the mitral annulus and measure MAPSE13 (figure 3). 
However, M-mode echocardiographic MAPSE assessment suffers from angle 
dependence issues. 
Measurements are usually performed at the septal and/or lateral annulus level from 
the apical 4-chamber view, using the zoom function. MAPSE is conventionally 
measured as the distance between the nadir of the M-mode annular motion profile—
corresponding to the maximal backward displacement from left ventricle apex after 
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the electrocardiographic P wave—and the peak shortening, i.e., the point of 
maximum upward excursion towards left ventricle apex. Because annular excursion 
reflects the global performance of left ventricle sub-endocardial longitudinal fibers, 
MAPSE is currently used as an index of global left ventricle longitudinal systolic 
function. A lateral MAPSE of 10 mm is commonly used to identify normality 14. 
Measurement of MAPSE has the advantage of being simple, highly reproducible, 
quickly performed, and feasible in nearly all patients even in the presence of 
suboptimal image quality 15. 
 
 
Figure 3. Measurement of MAPSE using the M-mode imaging of the lateral mitral annular 
motion 
 
 
MAPSE can also be measured by CMR in 4-chamber view. Lateral mitral annular 
positions can be marked at end-diastole, the images is advanced frame-by-frame to 
end-systole (just before mitral valve opening) where lateral mitral annular position 
is again identified. Lateral MAPSE is defined as the distance between the lateral 
mitral annular position at end-diastole to the lateral mitral annular position at end-
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systole. Thus, MAPSE is measured as the simple linear displacement between end-
diastole and end-systole (Figure 4).  
 
Figure 4. Assessment of lateral MAPSE in 4-chamber cardiac magnetic resonance. Lateral 
mitral annular positions was recorded at end diastole (left panel, red dot) and end systole (right 
panel, red line), allowing for assessment of lateral MAPSE 
 
 
Strain analysis 
There are three different types of myocardial deformation (figure 5). The sum of 
the three different longitudinal strain represents myocardial deformation directed 
from the base to the apex. During systole, ventricular myocardial fibers shorten with 
a translational movement from the base to the apex; the consequent reduction of the 
distance between single kernels is represented by negative trend curves. Through 
longitudinal strain analyses in 4-chamber, 2-chamber, 3-chamber and apical long-
axis views, both regional (relative to each of the 17 LV segments) and global strain 
values (global longitudinal strain) can be obtained. GLS recently has been validated 
as a quantitative index for global LV function. Normal reference ranges for GLS 
have been determined by meta-analysis of study control groups and healthy 
volunteers. In 24 studies involving 2,597 subjects, normal values ranged from 
15.9% to 22.1% (mean 19.7%; 95% CI: 20.4 to 18.9%)16.The same measurement 
can be applied to the speckle-tracking echocardiographic analysis of longitudinal 
myocardial deformation of the left ventricle and right ventricle, obtaining the peak 
atrial longitudinal strain and the right ventricle longitudinal strain respectively.  
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Figure 5. Speckle-tracking echocardiographic analysis of myocardial deformation showing 
measurements of longitudinal strain (upper), radial strain (intermediate), and circumferential 
strain (lower). 
Sergio Mondillo and al. Speckle-Tracking Echocardiography. A New Technique for Assessing 
Myocardial Function.  J Ultrasound Med 2011; 30:71–83 
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Speckle Tracking 2D Strain 
Recently, enormous interest has been generated by development of 
echocardiographic 2D speckle tracking techniques to assess long axis function in a 
more global manner by measuring GLS17 18 19. The raw ultrasonic signal or radio 
frequency signal that creates the ultrasonic image consists of numerous random 
speckles. Any given point on an ultrasonic image can be identified by its unique 
speckle pattern. Using these speckle patterns (speckle tracking) to identify specific 
points in the myocardium, strain can be calculated and displayed. Because 2D echo 
is distance, the initial measurement is strain. There is a variety of ways to 
demonstrate or present this strain information. By tracking the displacement of 
speckles during the cardiac cycle, speckle-tracking echocardiography allows 
semiautomated elaboration of myocardial deformation in 3 spatial directions: 
longitudinal, radial, and circumferential. In addition, speckle-tracking 
echocardiography offers an evaluation of the occurrence, direction, and velocity of 
left ventricle rotation 20. The semiautomated nature of speckle-tracking 
echocardiography guarantees good intraobserver and interobserver reproducibility 
21. 
 
CMR feature tracking 
Recent development of CMR feature tracking technology shows promise in 
allowing measurement of longitudinal strain using routine cine images in the 
clinical setting22. The underlying principle is based on recognition of ‘patterns of 
features’ or ‘irregularities’ in the image that are tracked and followed in successive 
images22. 
Importantly, this approach can be applied to routine cine CMR acquisitions thus 
avoiding the need for dedicated pulse sequences. 
Similar to echo speckle tracking, there are inter-vendor differences in the exact 
algorithms used in CMR feature tracking. Moreover, measurements are not 
necessarily directly comparable between modalities, or with those based on 
dedicated CMR pulse sequences. Nevertheless, several recent studies comparing 
14 
 
speckle tracking echo and CMR feature tracking have suggested good agreement23 
24. 
 
MAPSE and GLS 
MAPSE and GLS provide differing measures of left ventricular function. GLS uses 
specialized software to give a global measure of relative longitudinal change in 
length by tracking patterns within the myocardium and can also provide segmental 
information. By contrast, lateral MAPSE is a simple measure of displacement 
which incorporates primarily basal longitudinal movement and possibly an element 
of mitral annular radial contraction25. It requires no specialized software for its 
measurement. So far, there has been no analysis of the relative prognostic value of 
these two parameters. Therefore, the relative prognostic value of speckle tracking 
derived GLS and MAPSE would be very interesting. 
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Methods of the studies 
In the first study we prospectively enrolled four hundred consecutive outpatients 
referred at the Illinois University of Chicago for clinical CMR. We excluded 
patients with metallic implants incompatible with CMR, glomerular filtration < 30 
ml/min, severe claustrophobia, or mitral valve replacement. Information on 
demographic variables and laboratory testing was obtained from patient interviews 
and the electronic medical record.  Patients were followed for the combined primary 
outcome of MACE: death, non-fatal myocardial infarction, hospitalization for heart 
failure or unstable angina, and late revascularization (>90 days after CMR). Clinical 
follow-up was obtained by review of the electronic medical records. The Social 
Security Death Index was used to confirm all cases of death. 
In the second, third and fourth study, four geographically diverse universities in the 
United States (University of Illinois at Chicago, Duke University, New York 
Methodist, Houston de Bakey) participated in these observational, multicenter 
studies, the University of Illinois in Chicago served as the data coordinating center. 
We used a cloud-based database containing de-identified searchable data from 
consecutive patients with full DICOM datasets from the participating centers. 
Baseline demographics were obtained by local site investigators at the time of the 
clinical study. 
We enrolled 1060 patients with an ejection fraction <50% in the second study, 1,735 
hypertensives patients in the third study, 1047 patients with an ejection fraction 
<50% in the fourth study, who had undergone clinical CMR in 2011 at the involved 
Universities with both cine and late gate enhancement (LGE) imaging. Patients 
were followed for the primary outcome of all-cause mortality using the Social 
Security Death Index. 
In the single center part of the fourth study, consecutive patients (n=470) 
undergoing CMR at the Illinois University of Chicago, with both cine and LGE 
imaging with EF <50%, were included retrospectively. Comprehensive 
phenotyping, including clinical history, imaging, and cardiac catheterization, 
classified 330 individuals with ischemic and 140 with non-ischemic 
cardiomyopathy. Patients were followed for the primary outcome of all-cause 
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mortality using the US Social Security Death Index.  
 
Statistical analysis 
Normally distributed data were expressed as mean ± SD. Continuous variables were 
compared by the Student’s t-test or Wilcoxon rank-sum (depending on data 
normality). Comparisons of discrete variables were made using the chi-square test; 
Fisher’s exact test was used when the assumptions of the chi-square test were not 
met. Kaplan-Meier methods (log-rank) were used to evaluate the relationship 
between lateral MAPSE or GLS and time to the primary outcome of MACE or all-
cause mortality. Cox proportional hazards regression modelling was used to 
identify factors that were independently associated with MACE or all-cause 
mortality. All models were assessed for collinearity and proportional hazards 
assumption. For the multivariable model, risk factors which were univariate 
predictors at p≤0.10 were considered as candidate variables. To assess the added 
prognostic value of lateral MAPSE and GLS, the final model was compared with a 
model in which lateral MAPSE or GLS was not included. The global chi-square 
statistic was calculated for both models, and compared using the likelihood ratio 
test. Model discrimination was compared by calculating the C-statistic as well as 
the integrated discrimination improvement (IDI), which measures the improvement 
in sensitivity and specificity of the model with addition of the new predictor. Formal 
risk reclassification analyses were conducted with calculation of continuous net 
reclassification improvement (NRI) as well as categorical NRI using categories of 
<10%, 10–20%, and ≥20% mortality to define low, intermediate, and high-risk 
categories, respectively. A p value of <0.05 was considered statistically significant. 
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Study 1 
 
MAPSE and MACE 
The first part of our research focused on the correlation between MAPSE and 
MACE. We hypothesized that MAPSE measured during CMR imaging reflects 
changes in long axis function and may be an early marker for adverse 
cardiovascular outcomes. The aim of this study was to assess whether MAPSE is a 
predictor of MACE.  
 
Results 
Table 1 summarizes baseline patient characteristics. Median MAPSE for the 
population was 1.11 cm. Moreover, LVEF was significantly higher in patients with 
MAPSE ≥ 1.11 cm. 
A total of 72 MACE occurred during a median follow-up of 14.5 months. This was 
comprised of 11 deaths, 10 non-fatal myocardial infarctions, 12 hospitalizations for 
heart failure, 28 hospitalizations for unstable angina, and 11 late revascularizations. 
Overall, patients with lateral MAPSE <median had twice the number of cumulative 
MACE when compared to those with lateral MAPSE ≥ median (24 % vs 12 %, p = 
0.0018). By Kaplan-Meier analysis, patients with lateral MAPSE < median 
experienced significantly higher incidence of MACE than patients with lateral 
MAPSE ≥ median (log- rank p = 0.027) (Fig. 6). 
18 
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Figure 6. Kaplan Meier curves for MACE in patients with lateral MAPSE above and below 
the median. The number of patients at risk at each time interval for each group is presented 
 
 
 
By univariable analysis, age, diabetes, hypertension, NYHA class, LV mass and 
lateral MAPSE were associated with occurrence of MACE (at p ≤ 0.10) (Table 2). 
The highest cumulative incidence of MACE occurred in those with MAPSE < 
median and LVEF < 55%. In the multivariable analysis after adjustment for 
established clinical risk factors which were univariate predictors, lateral MAPSE 
remained a significant independent predictor of MACE (HR = 4.384, 95% CI 1.257-
15.271, per cm decrease; p = 0.020) (Table 2). Addition of lateral MAPSE to this 
model resulted in a significant increase in global chi-square as assessed by the 
likelihood ratio test (p = 0.03) and an integrated discrimination improvement of 
0.01 (p = 0.01). Overall, the net reclassification improvement (NRI) was 0.18 (p = 
0.006) across risk categories of MACE. 
 
20 
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Study 2 
 
MAPSE and mortality in patients with reduced EF 
At this stage, we wanted to evaluate the prognostic value of lateral MAPSE in a 
large multicenter population of patients with reduced ejection fraction undergoing 
CMR at several centers in the United States.  
 
Results 
Table 3 summarizes baseline patient characteristics. Mean lateral MAPSE for the 
population was 9.1mm. Median lateral MAPSE was 9.0mm (interquartile range: 
7.8-10.0 mm).  
A total of 132 deaths occurred during a median follow-up of 4.4 years (interquartile 
range: 3.6-5.1 years). 
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Table 3. Baseline Characteristics stratified by tertiles of lateral MAPSE. ACE = angiotensin 
converting enzyme, ARB = angiotensin receptor blocker, BMI = body mass index, LVEDV 
= LV end diastolic volume index, LVEF = LVEF, LVESV = LV end systolic volume index. 
*Except where indicated, data are numbers of patients, with percentages in parentheses. 
†Data are means ± standard deviations. 
 
 
By Kaplan-Meier analysis, the risk of death increased significantly with decreasing 
tertiles of lateral MAPSE (log-rank p=0.0001) (Figure 7). Kaplan-Meier analysis of 
patients with EF≤35% vs. those with EF>35% stratified by the highest and lowest 
tertiles of lateral MAPSE shows that mortality was significantly higher in patients 
with lower lateral MAPSE, irrespective of EF (Figure 8). 
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Figure 7. Kaplan Meier curves of lateral MAPSE stratified by tertiles of lateral MAPSE 
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Figure 8. Kaplan Meier curves stratified by ejection fraction 
 
 
After adjustment for risk factors which were univariate predictors at p≤0.15 (age, 
body mass index, diabetes, LV end-diastolic volume index, LGE, EF), lateral 
MAPSE remained a significant independent predictor of death (HR=1.724, 95% CI, 
1.571-1.892, per mm decrease; p<0.001) (Table 4).  Addition of lateral MAPSE to 
this model resulted in a significant increase in global chi-square as assessed by the 
likelihood ratio test (global chi-square increased from 50.54 to 203.94; p<0.0001) 
and an integrated discrimination improvement of 0.192 (95% CI 0.133, 0.258). 
Moreover, addition of lateral MAPSE resulted in significant improvement in model 
discrimination as assessed by the C statistic (C statistic increased from 0.675 to 
0.844 p<0.0001). 
Overall, the categorical net reclassification improvement (NRI) was 0.507 (95% CI, 
0.312-0.684); 0.279 (95% CI, 0.147-0.450) for patients with events, and 0.228 
(95% CI 0.120-0.300) for patients without events. Continuous NRI was 1.036 (95% 
CI, 0.878-1.194). 
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Table 4. Multivariable model of mortality. BMI=Body Mass Index, CI=Confidence Interval, 
LGE=Late Gadolinium Enhancement, LVEDV =Left Ventricular End Diastolic Volume 
Index, LVEF=Left Ventricular Ejection Fraction, MAPSE=Mitral Annular Plane Systolic 
Excursion. * per mm decrease. 
 
 
 
VARIABLES 
 
Multivariable 
  
 
Hazard Ratio  
(95% CI) 
 
P Value 
Age 1.019 (1.007-1.032) 0.003 
BMI 1.012 (1.001-1.023) 0.032 
Diabetes 1.588 (1.110-2.272) 0.011 
LVEDV index  1.000 (0.996-1.005) 0.857 
Lateral MAPSE * 1.724 (1.571-1.892) <0.001 
LGE present 1.916 (1.254-2.929) 0.003 
LVEF  1.023 (0.992-1.048) 0.057 
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Study 3 
 
MAPSE and mortality in patients with hypertension 
We then, given the known adverse consequences of myocardial involvement in 
hypertension, hypothesized that CMR-derived lateral MAPSE may provide 
incremental prognostic information in these patients. In patients with hypertension, 
the heart is a major target of end organ damage. Moreover, cardiac abnormalities 
including left ventricular hypertrophy and dysfunction have been shown to be 
powerful predictors of adverse outcomes in these individuals26. As a consequence, 
echocardiographic evaluation of myocardial structure and function is commonly 
used in the risk assessment of patients with hypertension27. 
 
Results 
Table 5 summarizes baseline patient characteristics stratified by lateral MAPSE 
above and below the median (10mm). 
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 Table 5. baseline patient characteristics stratified by lateral MAPSE above and below the 
median (10mm) 
 
 
CHARACTERISTICS 
 
 
Total 
 
 
 
 
MAPSE 
<10mm 
 
MAPSE 
≥10mm 
 
P Value 
Age (±SD), years 62.6 (±13.2) 64.5 (±13.1) 60.9 (±13.1) <0.001 
Male % 57.5 59.3 55.9 0.180 
BMI (±SD), kg/m2 30.0 (±8.8) 29.7 (±10.6) 30.4 (±6.6) 0.073 
Diabetes % 34.5 37.7 31.5 0.007 
Hyperlipidemia % 64.2 66.2 62.3 0.088 
Smoking % 11.4 13.3 9.8 0.023 
History of MI % 21.6 25.8 18.1 <0.001 
Aspirin % 62.0 67.0 57.3 <0.001 
Statin % 57.3 59.9 54.9 0.038 
ACE inhibitor or ARB % 50.2 55.8 44.9 <0.001 
Beta Blocker % 39.0 45.2 33.2 <0.001 
Diuretic % 43.6 49.5 38.0 <0.001 
Heart Rate (±SD), beats/min 73.4 (±15.0) 77.3 (±15.7) 69.7 (±13.2) <0.001 
Systolic BP (±SD), mmHg 131.7(±21.2) 129.0(±21.1) 134.2(±21.1) <0.001 
Diastolic BP (±SD), mmHg 75.0(±13.3) 75.4(±13.6) 74.5(±13.1) 0.210 
LVEDV index (±SD), ml/m2 75.5 (±31.7) 83.1 (±35.4) 68.2 (±25.8) <0.001 
LVESV index (±SD), ml/m2 39.4 (±30.1) 50.6 (±33.8) 28.7 (±21.3) <0.001 
LV mass index (±SD), g/m2 97.4 (±39.8) 105.4 (±42.2) 89.9 (±35.9) <0.001 
LGE present % 42.7 55.6 30.5 <0.001 
LGE extent (±SD), % 5.1 (±8.7) 7.1 (±9.8) 3.3 (±6.9) <0.001 
LVEF (±SD), % 49.3 (±17.4) 41.2 (±17.0) 57.0 (±13.9) <0.001 
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Of the 1,735 patients in this study, 235 died during a median follow-up of 5.1years 
(interquartile range: 3.4-6.1 years). 
When stratified by the median value of lateral MAPSE (10mm), Kaplan-Meier 
analysis showed significantly increased risk of death in those with lateral 
MAPSE<median (log-rank p<0.0001) (Figure 9).  
 
Figure 9. Kaplan Meier curves of lateral MAPSE stratified by the median value of lateral 
MAPSE (10mm) 
 
 
After adjustment for clinical and imaging risk factors, which were univariate 
predictors at p≤0.10 (age, gender, diabetes, history of MI, ACE or ARB use, diuretic 
use, heart rate, systolic BP, diastolic BP, LV end-diastolic volume index, LV end-
systolic volume index, LV mass index, LGE, EF), lateral MAPSE remained a 
significant independent predictor of death (HR=1.402, 95% CI 1.323-1.486, per 
mm decrease; p<0.001) i.e. each 1mm worsening in lateral MAPSE was associated 
with an 40.2% increase risk of death (Table 6). Addition of lateral MAPSE into the 
model with clinical and imaging predictors resulted in significant increase in the C-
statistic (from 0.735 to 0.815 p<0.0001) and an integrated. GLS was also measured, 
it remained a significant predictor of events in the final multivariable model. Thus, 
both lateral MAPSE and GLS were independently associated with death in this 
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population. Moreover, there was no evidence of problematic strong collinearity 
between GLS and lateral MAPSE (variance inflation factor was 1.37). 
 
Table 6. Uni and multivariable model of mortality with lateral MAPSE adjusted to univariate 
clinical and imaging predictors (at p≤0.10) for the whole population. ACE=Angiotensin 
Converting Enzyme, ARB=Angiotensin Receptor Blocker, BMI=Body Mass Index, LGE=Late 
Gadolinium Enhancement, LVEDV =Left Ventricular End Diastolic Volume Index, 
LVEF=Left Ventricular Ejection Fraction, LVESV =Left Ventricular End Systolic Volume 
Index, MAPSE=Mitral Annular Plane Systolic Excursion, MI=Myocardial Infarction, 
SD=standard deviation. * per mm decrease. ‡ per % decrease. 
 
 
 
 
VARIABLES 
 
 
Univariable 
 
 
 
 
Multivariable 
  
 
Hazard Ratio  
(95% CI) 
 
P 
Value 
 
Hazard Ratio  
(95% CI) 
 
P 
Value 
Age 1.034 (1.023-1.045) <0.001 1.021 (1.010-1.033) <0.001 
Male 1.413 (1.073-1.859) 0.014 - - 
BMI  0.983 (0.963-1.003) 0.095 - - 
Diabetes 1.372 (1.057-1.781) 0.018 - - 
Hyperlipidemia  1.074 (0.819-1.409) 0.606 - - 
Smoking 1.176 (0.786-1.758) 0.430 - - 
History of MI 1.394 (1.043-1.863) 0.025 - - 
Aspirin 1.194 (0.907-1.571) 0.205 - - 
Statin 0.972 (0.746-1.267) 0.833 - - 
ACE inhibitor or 
ARB 
0.673 (0.429-1.055) 0.084 - - 
Beta Blocker 1.006 (0.762-1.327) 0.968 - - 
Diuretic 1.472 (1.132-1.913) 0.004 - - 
Heart Rate  1.023 (1.016-1.031) <0.001 1.013 (1.004-1.021) 0.004 
Systolic BP  0.992 (0.985-0.998) 0.009 - - 
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Diastolic BP  0.984 (0.974-0.994) 0.002 0.983 (0.973-0.993) 0.001 
LVEDV index  1.006 (1.002-1.010) 0.001 - - 
LVESV index  1.008 (1.005-1.012) <0.001 - - 
LV mass index  1.004 (1.001-1.007) 0.005 - - 
LGE  2.701 (2.061-3.541) <0.001 1.622 (1.211-2.174) 0.001 
Lateral MAPSE* 1.477 (1.403-1.555) <0.001 1.402 (1.323-1.486) <0.001 
GLS 1.210 (1.180-1.240) <0.001 1.180 (1.137–1.224) <0.001 
LVEF ‡ 1.024 (1.016-1.031) <0.001 - - 
 
 
Seventy-seven deaths occurred amongst the 896 patients with preserved EF 
(≥50%).  When stratified by the median value of lateral MAPSE (12mm), Kaplan-
Meier analysis showed significantly increased risk of death in those with lateral 
MAPSE<median (log-rank p<0.0001) (Figure 10). Each 1mm decrease in lateral 
MAPSE was associated with a 33.9% increase risk-of-death after adjustment for 
clinical and imaging risk factors (HR=1.339; p<0.001) (Table 7). GLS remained a 
significant predictor of events in the final multivariable model (HR: 1.210; p < 
0.001). Thus, both MAPSE and GLS were independently associated with death in 
this subpopulation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
31 
 
Figure 10. Kaplan Meier curves in patients with preserved ejection fraction stratified by the 
median value of lateral MAPSE (12mm). 
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Table 7. Multivariable model of mortality with lateral MAPSE adjusted to univariate clinical 
and imaging predictors (at p≤0.10) for patients with preserved ejection fraction. 
ACE=Angiotensin Converting Enzyme, ARB=Angiotensin Receptor Blocker, BMI=Body 
Mass Index, LGE=Late Gadolinium Enhancement, LVEDV =Left Ventricular End Diastolic 
Volume Index, LVEF=Left Ventricular Ejection Fraction, LVESV =Left Ventricular End 
Systolic Volume Index, MAPSE=Mitral Annular Plane Systolic Excursion, MI=Myocardial 
Infarction, SD=standard deviation. * per mm decrease. ‡ per % decrease. 
 
 
VARIABLES 
 
Univariable 
 
 
 
Multivariable 
  
 
Hazard Ratio  
(95% CI) 
 
P 
Value 
 
Hazard Ratio  
(95% CI) 
 
P 
Value 
Age 1.049 (1.028-1.071) <0.001 1.040 (1.018-1.064) <0.001 
Male 1.548 (0.959-2.500) 0.070 - - 
BMI  0.948 (0.912-0.985) 0.004 0.955 (0.917-0.994) 0.025 
Diabetes 1.378 (0.865-2.197) 0.185 - - 
Hyperlipidemia  0.932 (0.593-1.463) 0.758 - - 
Smoking 0.571 (0.180-1.812) 0.299 - - 
History of MI 0.897 (0.390-2.066) 0.796 - - 
Aspirin 1.010 (0.644-1.584) 0.966 - - 
Statin 1.078 (0.685-1.696) 0.745 - - 
ACE inhibitor or 
ARB 
0.960 (0.604-1.523) 0.859 - - 
Beta Blocker 0.855 (0.499-1.465) 0.563 - - 
Diuretic 1.497 (0.948-2.362) 0.087 - - 
Heart Rate  1.025 (1.011-1.040) <0.001 1.025 (1.010-1.040) 0.001 
Systolic BP  1.001 (0.990-1.012) 0.828 - - 
Diastolic BP  0.991 (0.973-1.009) 0.308 - - 
LVEDV index  0.993 (0.980-1.005) 0.250 - - 
LVESV index  1.001 (0.981-1.022) 0.916 - - 
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LV mass index  1.002 (1.001-1.003) 0.025 1.008 (1.001-1.015) 0.020 
LGE  1.955 (1.214-3.151) 0.008 - - 
Lateral MAPSE* 1.417 (1.300-1.545) <0.001 1.339 (1.224-1.465) <0.001 
GLS 1.269 (1.211-1.330) <0.001 1.210 (1.147-1.277) <0.001 
LVEF ‡ 1.035 (1.000-1.071) 0.046 - - 
 
 
One hundred and seventy-two deaths occurred amongst the 1,360 patients without 
history of myocardial infarction. When stratified by the median value of lateral 
MAPSE (10.4mm), Kaplan-Meier analysis showed significantly increased risk of 
death in those with lateral MAPSE<10.4 mm (log-rank p<0.0001) (Figure 11). Each 
1mm decrease in lateral MAPSE was associated with a 39.0% increase risk-of-
death after adjustment for clinical and imaging risk factors (HR=1.390; p<0.001) 
(Table 8). GLS remained a significant predictor of events in the final multivariable 
model (HR: 1.159; p < 0.001). Thus, both MAPSE and GLS were independently 
associated with death in this subpopulation. 
 
 
Figure 11. Kaplan Meier curves in patients history of myocardial infarction stratified by the 
median value of lateral MAPSE (10.4mm). 
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Table 8. Multivariable model of mortality with lateral MAPSE adjusted to univariate clinical 
and imaging predictors (at p≤0.10) for patients without history of myocardial infarction. 
ACE=Angiotensin Converting Enzyme, ARB=Angiotensin Receptor Blocker, BMI=Body 
Mass Index, LGE=Late Gadolinium Enhancement, LVEDV =Left Ventricular End Diastolic 
Volume Index, LVEF=Left Ventricular Ejection Fraction, LVESV =Left Ventricular End 
Systolic Volume Index, MAPSE=Mitral Annular Plane Systolic Excursion, MI=Myocardial 
Infarction, SD=standard deviation. * per mm decrease. ‡ per % decrease. 
 
 
 
 
VARIABLES 
 
 
Univariable 
 
 
 
 
Multivariable 
  
 
Hazard Ratio  
(95% CI) 
 
P 
Value 
 
Hazard Ratio  
(95% CI) 
 
P 
Value 
Age 1.040 (1.027-1.053) <0.001 1.026 (1.013-1.039) <0.001 
Male 1.467 (0.903-2.385) 0.118 - - 
BMI  0.961 (0.937-0.986) 0.002 - - 
Diabetes 1.453 (1.070-1.972) 0.018 - - 
Hyperlipidemia  1.138 (0.836-1.550) 0.409 - - 
Smoking 1.283 (0.766-2.148) 0.360 - - 
Aspirin 1.159 (0.851-1.578) 0.347 - - 
Statin 1.054 (0.776-1.431) 0.738 - - 
ACE inhibitor or 
ARB 
1.123 (0.828-1.522) 0.457 - - 
Beta Blocker 1.099 (0.793-1.522) 0.572 - - 
Diuretic 1.520 (1.118-2.066) 0.008 - - 
Heart Rate  1.022 (1.013-1.031) <0.001 1.012 (1.002-1.022) 0.018 
Systolic BP  0.995 (0.987-1.002) 0.166 - - 
Diastolic BP  0.985 (0.973-0.996) 0.009 0.982 (0.971-0.994) 0.002 
LVEDV index  1.004 (1.000-1.009) 0.070 - - 
LVESV index  1.007 (1.003-1.012) 0.002 - - 
LV mass index  1.004 (1.001-1.007) 0.021 - - 
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LGE  2.960 (2.187-4.006) <0.001 1.721 (1.236-2.397) 0.001 
Lateral MAPSE* 1.477 (1.393-1.567) <0.001 1.390 (1.299-1.486) <0.001 
GLS 1.211 (1.178-1.245) <0.001 1.159 (1.112-1.207) <0.001 
LVEF ‡ 1.022 (1.031-1.071) <0.001 - - 
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Study 4 
GLS and mortality in patients with reduced EF 
 
The single center study 
The aim of this study was to evaluate the prognostic-value of CMR feature-tracking 
derived GLS in a single center-population of patients undergoing evaluation for 
ischemic or non-ischemic dilated cardiomyopathy.  
 
Results 
The mean age of the study population was 60±15years. Sixty-nine percent were 
male and 30% had diabetes mellitus. The mean EF was 34.2±9.8%. Mean GLS was 
‒10.4±4.6%. Median GLS was ‒10.3% (interquartile range, ‒7.1 to ‒13.6%). 
During a median follow-up of 4.1years (interquartile range, 3.5–4.8 years), 
93(19.8%) patients died. By Kaplan-Meier analysis, the risk of death increased 
significantly with worsening tertiles of GLS (log-rank P<0.0001) (figure 12). 
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Figure 12. Kaplan Meier curves of GLS stratified by tertiles of GLS 
 
 
After adjustment for clinical and imaging characteristics (age, body mass index, 
diabetes mellitus, hypertension, etiology of cardiomyopathy, left ventricular end 
diastolic volume index, LGE size, EF), which had univariable associations with 
death (at P≤0.20), GLS remained significantly associated with death (HR, 2.35 per 
%; 95% CI, 1.81–3.06; P<0.001). In this model, EF remained significantly 
associated with death (HR, 0.95 per %; 95% CI, 0.91–0.99; P=0.038) but LGE size 
was not (HR, 1.02 per %; 95% CI, 0.99–1.04; P=0.186). Addition of GLS in this 
model resulted in significant improvement in the global χ2 (31–157; P < 0.0001) 
and C-statistic (0.64–0.85; P<0.0001). Continuous net reclassification 
improvement was 1.16 (95% CI, 0.95–1.38), with an integrated discrimination 
improvement of 0.32 (95% CI, 0.22–0.40). 
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The multicentre study 
We then extended this study to a large multicenter population of patients with 
cardiomyopathy undergoing CMR at several centers in the United States. 
 
Results 
Table 9 summarizes baseline patient characteristics. 
 
Table 9. Baseline Characteristics. ACE=Angiotensin Converting Enzyme, ARB=Angiotensin 
Receptor Blocker, BMI=Body Mass Index, GLS=Global Longitudinal Strain, LGE=Late 
Gadolinium Enhancement, LVEDV =Left Ventricular End Diastolic Volume Index, 
LVEF=Left Ventricular Ejection Fraction, LVESV =Left Ventricular End Systolic Volume 
Index, MI=Myocardial Infarction, SD=standard deviation. 
 
 
Of the 1012 patients in the study, 133 died during a median follow-up of 4.4 years 
(interquartile range: 3.6-5.1 years). 
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By Kaplan-Meier analysis, the risk of death increased significantly with worsening 
tertiles of GLS (log-rank p<0.0001) (Figure 13).  
 
Figure 13. Kaplan Meier curves of GLS stratified by tertiles of GLS 
 
After adjustment for risk factors, which were univariate predictors at p≤0.20 (age, 
body mass index, diabetes, hyperlipidemia, LV end-diastolic volume index, LGE, 
EF), GLS remained a significant independent predictor of death (HR=1.888 per 
percentage decrease p<0.001) (Table 10).  Addition of GLS in this model resulted 
in a significant increase in global Chi-square as assessed by the likelihood ratio test 
(increasing from 43.14 to 238.33; p<0.0001) and an integrated discrimination 
improvement of 0.261 (95% CI, 0.196-0.332) with a continuous NRI of 1.215 (95% 
CI, 1.023-1.333). Moreover, addition of GLS resulted in significant improvement 
in model discrimination as assessed by the C-statistic (increased from 0.668 to 
0.848 p<0.0001). Finally, model global Chi-square and C-statistics showed 
significant and incremental increase when imaging markers were added to clinical 
variables in a hierarchical manner (Figure 14). 
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Table 10. Multivariable model of mortality. BMI=Body Mass Index, CI=Confidence Interval, 
GLS=Global Longitudinal Strain, LGE=Late Gadolinium Enhancement, LVEDV =Left 
Ventricular End Diastolic Volume Index, LVEF=Left Ventricular Ejection Fraction. 
 
 
 
VARIABLES 
 
Multivariable 
  
 
Hazard Ratio  
(95% CI) 
 
P Value 
Age 1.016 (1.005-1.027) 0.046 
BMI 1.000 (0.990-1.009) 0.925 
Diabetes 1.556 (1.066-2.271) 0.022 
Hyperlipidemia 0.732 (0.493-1.087) 0.122 
LVEDV index  0.999 (0.995-1.002) 0.559 
GLS 1.888 (1.546-2.305) <0.001 
LGE present 1.327 (0.684-2.038) 0.197 
LVEF  1.005 (0.969-1.042) 0.787 
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Figure 14. Chi square and C-statistics showed significant and incremental increase when 
imaging markers were  added to clinical variables 
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Discussion 
 
MAPSE 
MAPSE - as a surrogate for LV long axis function - is a powerful independent 
predictor of morbidity and mortality. Moreover, we have demonstrated that it 
provides prognostic information additional to common clinical and imaging risk 
factors including EF and LGE. Measurements of lateral MAPSE can be obtained 
from standard cine CMR images without the need for propriety software. These 
findings may have implications for management decisions based on risk 
stratification of patients with cardiomyopathy and LV dysfunction. How this 
information will impact clinical care requires further study. However, it is 
interesting to note that we found that patients with relatively preserved lateral 
MAPSE (>10mm) had very few adverse events regardless of whether their EF was 
above or below 35%. Given that current guidelines recommend ICD placement 
based primarily on an EF≤35%, it will be interesting to examine the role of long-
axis function on sudden cardiac death in future studies. 
MAPSE measured using echocardiography has been shown to be a predictor of 
adverse cardiovascular outcomes in a number of conditions including myocardial 
infarct, heart failure, atrial fibrillation28 29 30 31.  However, M-mode MAPSE 
assessment suffers from angle dependence issues, which were overcome when 
using CMR as in this study.  
Riffel and colleagues showed similar findings using a surrogate CMR measure of 
long-axis strain derived from the movement of the mitral annulus relative to the 
apex32. Their study patients (n=146) were individuals with non-ischemic 
cardiomyopathy and EF ≤45 % who were followed for a median of 4.3 years for a 
composite primary outcome of cardiac death, heart transplantation or aborted 
sudden cardiac death. Gjesdal et al. examined the prognostic value of similarly 
derived CMR long axis function from 1,651 individuals in the MESA cohort who 
were free of cardiovascular disease33. 
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In patients with hypertension, the heart is a major target of damage. Moreover, 
cardiac abnormalities including left ventricular hypertrophy and dysfunction have 
been shown to be powerful predictors of adverse outcomes in these individuals34 35. 
As a consequence, echocardiographic evaluation of myocardial structure and 
function is commonly used in the risk assessment of patients with hypertension. 
Prior echocardiographic studies have shown that MAPSE is significantly reduced 
in hypertensive patients even if ejection fraction is preserved36 37. In a small single 
center study, Ballo et al. examined the prognostic value of MAPSE in 156 patients 
with hypertension and preserved ejection fraction38. Over a mean follow-up of 23 
months, 24 patients suffered a composite endpoint of heart failure hospitalization, 
new-onset angina, nonfatal myocardial infarction, coronary revascularization, 
transient ischemic attack, stroke, and cardiovascular death. Moreover, MAPSE was 
found to be an independent predictor of the composite endpoint. 
 
The precise mechanism underlying the association between impaired lateral 
MAPSE and adverse outcomes is unclear. It has been suggested that the 
subendocardial myocardial fibers (which are more longitudinally aligned) are 
extremely sensitive to diseases because of greater compressive forces and higher 
oxygen consumption11 39 40 41. 
The subendocardial fibers are therefore more vulnerable to increased wall stress 
and imbalances between oxygen supply and demand which may be seen in early 
stages of hypertension. Interestingly, in an animal model of hypertension, 
longitudinal function was shown to progressively deteriorate with time compared 
to control animals and was associated with histological subendocardial fibrosis42 
 
GLS 
GLS, measured by feature tracking CMR, is a powerful independent predictor of 
mortality, in a large multicenter population of patients with cardiomyopathy.  
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There is now a large body of literature demonstrating the diagnostic and prognostic 
utility of GLS in various cardiovascular disorders43 44 45. Even in rare disease such 
as amyloidosis a reduction of GLS has been demonstrated46. Another recent 
study47 was designed to show the diagnostic importance of two-dimensional 
speckle-tracking imaging in differentiating cardiac amyloidosis from other causes 
of LV hypertrophy; the authors found that the amyloid heart is characterized by 
reduced basal strain and regional variations in LS from base to apex with a relative 
‘apical sparing’.  
However, these echo strain techniques are highly dependent on attainment of good 
quality imaging and there is lack of standardization between different vendors18. 
Moreover, suboptimal acoustic windows, apical foreshortening and far field drop 
out may result in time-consuming analysis requiring significant operator 
experience19. 
There is a significant and growing body of literature demonstrating the prognostic 
value GLS derived using speckle tracking echo in patients with cardiomyopathy17 
43 48 49. 
In contrast, data regarding CMR derived GLS and prognosis has been very limited 
so far. Buss and colleagues recently demonstrated that feature tracking derived GLS 
was an independent predictor of the composite endpoint of cardiac death, heart 
transplantation, and aborted sudden cardiac death in a small population of 210 
dilated cardiomyopathy patients followed for a median of 5.3 years50. Our findings 
are consistent with these prior studies in suggesting that after adjustment for GLS, 
LVEF is not a significant predicator of events. This study builds on prior data by 
demonstrating the independent and incremental prognostic value of CMR feature 
tracking GLS in a multicenter cardiomyopathy population - with a significantly 
greater number of patients and hard events. These findings greatly expand the 
evidence base for CMR derived GLS and prognosis. 
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Head-to-head comparison between MAPSE and GLS 
To the best of our knowledge, there has been no analysis of the relative prognostic 
value of these 2 parameters. The hypertension study has shown that both CMR-
derived lateral MAPSE and feature tracking GLS are independently associated with 
death in patients with hypertension and provide complimentary prognostic 
information. Lateral MAPSE provides incremental prognostic information to 
clinical and imaging variables including GLS. Conversely, GLS provides 
incremental prognostic information to clinical and imaging variables including 
lateral MAPSE. Given intermodality and intervendor differences in GLS 
acquisition methods, these findings are not necessarily applicable to 
echocardiography. Therefore, the relative prognostic values of speckle tracking-
derived GLS and echo-derived MAPSE require further study both in hypertension 
and in other conditions. 
 
Role of CMR in cardiomyopathies 
CMR has evolved into a major tool for diagnosis and prognostic assessment of 
patients with cardiomyopathy by providing data on morphology, function, 
perfusion, viability and tissue characterization51 52 53 54 55. It is the reference standard 
for measurement of ventricular volumes, mass, and function, allowing serial 
assessment of disease progression or treatment response in individual patients51 52 
54 55. CMR tissue characterization can help establish the underlying cause of a 
cardiomyopathy51 52 54 55. The presence and extent of LGE allows assessment of 
the likelihood of recovery of function after revascularization, medical therapy or 
cardiac resynchronization51 52 54 55. LGE is a powerful predictor of adverse 
cardiovascular outcome in wide range of cardiomyopathies51 52 54 55. In this study 
we have shown that GLS provides independent prognostic information in patients 
with cardiomyopathy undergoing CMR. Moreover, this was incremental to standard 
clinical and CMR variables including LGE and EF. How this information will 
impact clinical care requires further study. However, it is interesting to note that we 
found that patients with relatively preserved GLS had very few adverse events 
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regardless of whether their EF was above or below 35% or whether LGE was 
present or not. Given that current guidelines recommend ICD placement based 
primarily on an EF≤35%, it will be interesting to examine the role of GLS on sudden 
cardiac death in future studies. 
 
Role of CMR in Hypertension 
Echocardiography has a well-established role for assessment of cardiac end organ 
damage and prognosis in hypertension56 57. However, CMR is the gold standard for 
measurement of ventricular volumes, function and mass; and for myocardial tissue 
characterization with detection of myocardial fibrosis. As such it may play a role in 
assessment of some patients with hypertension and hypertensive heart disease58 59. 
It also allows identification of diseases that may mimic hypertensive LVH60. The 
presence of focal myocardial fibrosis as detected by LGE is a powerful predictor of 
adverse cardiovascular outcomes in numerous conditions including hypertension61 
62. Krittayaphong et al. showed that LGE is a powerful and independent predictor 
of cardiac death or myocardial infarction in a population of 1644 patients with 
hypertension followed for a mean of 29 months63. Likewise, LGE was a significant 
independent predictor of death in our patient cohort. Given the co-existence of 
coronary artery disease, LGE maybe seen in a subendocardial pattern as well as in 
a more patchy non-coronary mid-myocardial distribution58 64 65. Our study suggests 
that CMR can provide significant incremental prognostic information in patients 
with hypertension using lateral MAPSE as a marker of longitudinal function. 
Moreover, measurements of lateral MAPSE can be obtained from conventional cine 
CMR images without the need for specialized pulse sequences, propriety software, 
or additional imaging time. Better identification of high-risk hypertensive patients 
may allow closer follow-up and more directed therapies to be applied. How this 
information will affect clinical care requires further investigation and future studies 
are warranted to explore the role of CMR derived lateral MAPSE in clinical 
decision making. These studies will need to demonstrate that imaging driven patient 
management improves specific outcomes before such an approach could be 
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advocated. 
 
Conclusions 
We have shown that reduced long axis function assessed with lateral MAPSE 
during routine cine-CMR is an independent predictor of MACE and is a powerful 
independent predictor of mortality in patients with left ventricular dysfunction 
incremental to common clinical and imaging risk factors including EF and LGE. 
Even in patients with hypertension, MAPSE measured during routine cine-CMR is 
a significant independent predictor of mortality incremental to common clinical and 
imaging risk factors including EF, LV mass and LGE. A major strength of these 
findings is that they were made in a big multicenter group of hypertensive patients 
and patients with cardiomyopathy with a large number of hard events which greatly 
increases the robustness of our results.  
GLS measured during routine cine-CMR is a powerful independent predictor of 
mortality in patients with cardiomyopathy, incremental to common clinical and 
imaging risk factors including EF and LGE.  
Our findings highlight the role of long-axis function in individuals with 
hypertension and with cardiomyopathy and suggest that consideration may be given 
to measurement of lateral MAPSE and GLS in these patients. Future studies are 
needed to explore the role of CMR derived lateral MAPSE and GLS in clinical 
decision making for these patients. 
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